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Cancer anorexia–cachexia syndrome is characterized by decreased food intake, weight loss, muscle tissue wasting and
psychological distress, and this syndrome is a major source of increased morbidity and mortality in cancer patients. This study
aimed to clarify the gut–brain peptides involved in the pathogenesis of the syndrome and determine effective treatment for
cancer anorexia–cachexia. We show that both ghrelin insufﬁciency and resistance were observed in tumor-bearing rats.
Corticotropin-releasing factor (CRF) decreased the plasma level of acyl ghrelin, and its receptor antagonist, a-helical CRF,
increased food intake of these rats. The serotonin 2c receptor (5-HT2cR) antagonist SB242084 decreased hypothalamic CRF
level and improved anorexia, gastrointestinal (GI) dysmotility and body weight loss. The ghrelin receptor antagonist (D-Lys3)-
GHRP-6 worsened anorexia and hastened death in tumor-bearing rats. Ghrelin attenuated anorexia–cachexia in the short term,
but failed to prolong survival, as did SB242084 administration. In addition, the herbal medicine rikkunshito improved anorexia,
GI dysmotility, muscle wasting, and anxiety-related behavior and prolonged survival in animals and patients with cancer. The
appetite-stimulating effect of rikkunshito was blocked by (D-Lys3)-GHRP-6. Active components of rikkunshito, hesperidin and
atractylodin, potentiated ghrelin secretion and receptor signaling, respectively, and atractylodin prolonged survival in tumor-
bearing rats. Our study demonstrates that the integrated mechanism underlying cancer anorexia–cachexia involves lowered
ghrelin signaling due to excessive hypothalamic interactions of 5-HT with CRF through the 5-HT2cR. Potentiation of ghrelin
receptor signaling may be an attractive treatment for anorexia, muscle wasting and prolong survival in patients with cancer
anorexia–cachexia.
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Introduction
Cachexia is characterized by weight loss, fat and muscle
tissue wasting, psychological distress and a lower quality of
life. In cancer patients, anorexia development is frequently
associated with the presence of cachexia, resulting in the so-
called cancer anorexia–cachexia syndrome.
1 This syndrome
is observed in 80% of patients with advanced-stage cancer
and is a frequent cause of death.
2 Recent reports have
indicated that an imbalance between anorexigenic
and orexigenic peptides leads to appetite suppression.
3–5
Anorexia–cachexia is caused predominantly by cytokines
that are either produced by cancer cells or released by the
host immune system in response to the cancer,
6 but
the neurochemical mechanisms responsible for cancer
anorexia–cachexia remain uncertain. The two major options
for pharmacological therapy are megestrol acetate and
glucocorticoids,
7,8 but both have limited effectiveness.
A better understanding of the underlying mechanisms of this
syndrome will help in the development of new therapies to
improve quality of life and potentially to prolong survival in
patients with cancer-induced anorexia–cachexia.
Anxiety and depressive symptoms are associated with
various gastrointestinal (GI) disorders, including cancers,
6
chronic liver diseases, inﬂammatory bowel diseases and
functional GI diseases.
9,10 Corticotropin-releasing factor
(CRF) is a mediator of the endocrine, autonomic and immune
responses to stress, including anorexia and anxiety-related
behavior.
11 The central serotonin (5-HT) system has also
been implicatedintheprocessesofmealsatiationandsatiety.
Hypothalamic 5-HT and CRF activities are stimulated by
proinﬂammatory cytokines in the circulation and the hypotha-
lamus.
12 Therefore, we hypothesized that 5-HT and CRF
might have a role in the pathogenesis of cancer anorexia–
cachexia by modulating central and peripheral mechanisms
as part of the stress response.
Ghrelin system is involved in eliciting feeding, inducing
adiposity, and regulating glucose metabolism and body
weight.
13 Ghrelin has an important role in triggering the
adaptiveresponsetostarvation.Inthisstudy,wedemonstrate
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www.nature.com/tpthat cancer anorexia–cachexia is mediated by decreased
ghrelin signaling due to excessive hypothalamic interactions
of 5-HT and CRF through the 5-HT 2c receptor (5-HT2cR) in a
tumor-bearing rat model.
Materials and methods
Male Wistar rats were intraperitoneally (i.p.) inoculated with
AH-130 ascites hepatoma cells (Tohoku University, Sendai,
Japan). The effects of a-helical CRF, 5-HT2cR antagonist,
ghrelin, ghrelin receptor (GHS-R) antagonist, and rikkunshito
on food intake, weight and GI motility were examined in the
tumor-bearing rats. Anxiety-related behavior was estimated
using the open-ﬁeld test. Plasma levels of peptides were
determined by enzyme immunoassay. Ca
2þ imaging and
radioligand binding were performed using GHS-R-expressing
cells and rat single neurons isolated from the arcuate nucleus
(ARC) or paraventricular nucleus (PVN). In all, 39 patients
who had pathologically proven stage III/IV pancreatic cancer
with ascites were eligible candidates for rikkunshito, as
suggested from clinical experiences of this drug in Japan.
The patients were retrospectively analyzed from 2004 to
2009 in Chiba Cancer Center (Chiba, Japan). To assess the
difference among groups, a Student t-test or a multi-group
Dunnett test was performed. Mortality data were compared
using Kaplan–Meier plots and Gehan–Breslow–Wilcoxon
tests (see Supplementary Materials).
Results
Ghrelin and cancer anorexia–cachexia. Decreased food
intake, low rectal temperature, weight loss and wasting of
muscle and fat mass were observed after tumor injection in
rats (Figure 1a). Plasma concentrations of cytokines and
c-reactive protein (CRP) were elevated (Figure 1b). Plasma
acyl ghrelin concentrations were higher in tumor-bearing
rats than in free-fed normal rats, but were signiﬁcantly lower
than in pair-fed normal rats and had an inverse relationship
with plasma leptin concentrations (Figure 1c). Signiﬁcant
decreases in the hypothalamic expression of appetite-
regulating peptides, neuropeptide Y (NPY), agouti-related
peptide, proopiomelanocortin (POMC), urocortin-2,3 and
CRF, were observed in tumor-bearing rats compared to
pair-fed controls (Figure 1d). This indicates a pathogenetic
role of orexigenic peptides in cancer anorexia–cachexia.
Intravenous administration of ghrelin increased food intake
for 2h, but not 6h in normal and tumor-bearing rats on day
5 (Figure 1e). These responses were attenuated in tumor-
bearing rats compared with normal rats owing to ghrelin
resistance. In contrast, i.p. administration of the GHS-R
antagonist (D-Lys3)-GHRP-6 (4mmolkg
 1; data not shown)
worsened anorexia in tumor-bearing rats. Oral (per os)
administration of a 5-HT2cR antagonist, SB242084
(5mgkg
 1), increased food intake in tumor-bearing rats
(Figure 1f). The traditional herbal medicine rikkunshito, which
stimulates the secretion of endogenous acyl ghrelin by
blocking 5-HT2 receptors in rats,
14 also increased food intake
intumor-bearingrats(Figure1g).Theeffectofrikkunshitowas
inhibited by intravenous administration of (D-Lys3)-GHRP-6
(2mmolkg
 1), suggesting mediation by endogenous acyl
ghrelin. Daily administration of SB242084 or rikkunshito in
tumor-bearing rats inhibited weight loss without affecting
ascites volume (Supplementary Figure S1).
Phase III-like contractions in the antrum and duodenum of
normal fasted rats are mediated by orexigenic signaling from
ghrelin.
15 Tumor-bearing rats exhibited fed-like motor activ-
ities in the antrum and duodenum, and the frequency of their
phase III-like contractions signiﬁcantly decreased (Supple-
mentary Figure S2). Intravenous administration of ghrelin
(3nmol) to tumor-bearing rats on day 5 immediately poten-
tiated the fasted motor activity and increased the frequency of
the phase III-like contractions (Figure 1h). Oral administration
of SB242084 (1mgkg
 1) or rikkunshito (1000mgkg
 1)
gradually restored the fasted motor patterns (Supplementary
Figure S2).
Involvement of CRF in cancer anorexia. The cytosolic
Ca
2þ concentration ([Ca
2þ]i) in single neurons isolated from
the PVN of rats was measured by fura-2 microﬂuorometry.
Administration of 10
 5moll
 1 5-HT for 10–15min into
superfusion solutions increased the [Ca
2þ]i in a continuous
oscillatory manner. The 5-HT-induced [Ca
2þ]i increase was
inhibited by administration of 100mgml
 1 rikkunshito to the
PVN neurons; 83% of which subsequently demonstrated
immunoreactivity to CRF (Figure 2a). In contrast, rikkunshito
had little inhibitory effect on 30mmoll
 1 potassium chloride-
induced increases in [Ca
2þ]i (data not shown).
A signiﬁcant decrease in the plasma concentration of acyl
ghrelin was observed 3h after intracerebroventricular admin-
istration of CRF (1.5nmol) to fasted rats (Figure 2b),
suggesting that endogenous ghrelin secretion is regulated
by central CRF neurons. The electrophysiological study
demonstrated that ghrelin and rikkunshito inﬂuenced CRF-
regulated adrenal function by decreased adrenal sympathetic
nerve activity (Figure 2c).
Administration of a CRF antagonist, a-helical CRF (50mg,
intracerebroventricular), increased food intake in tumor-
bearing rats (Figure 2d), suggesting that the hypothalamic
CRF system is activated in tumor-bearing rats, despite
the overall reduction in CRF expression due to negative
feedback inhibition resulting from increased corticosterone
secretion (Figure 2e). CRF levels in the hypothalamus of
tumor-bearingratsweresigniﬁcantlydecreasedbySB242084
and rikkunshito (Figure 2f). CRF-treated animals are known
to display anxiety-related responses with decreased explo-
ratory behavior.
16 Tumor-bearing rats showed a signiﬁcant
decrease in rearing in the open-ﬁeld test and increased
fecal pellet output. Oral administration of rikkunshito to these
rats recovered rearing and reversed fecal pellet output
(Figure 2g).
Ghrelin signaling and rikkunshito. The afferent activity of
the gastric vagus nerve decreased with intravenous
administration of ghrelin (Figure 3a), as we have reported
previously.
17 In contrast, the efferent activities of the gastric
(Figure 3b) and celiac (data not shown) branches of the
vagus nerve increased with intravenous administration of
ghrelin (10ng). Similar effects were observed with
intraduodenal, but not intragastric, administration of
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Figure 1 Cancer anorexia–cachexia. (a) Food intake, rectal temperatures and weights of tumor-bearing rats (n¼6–8). (b–d) Plasma and hypothalamic appetite-regulating
peptides(n¼8–10).(e–g)Effectsofghrelin,theserotonin2creceptor(5-HT2cR)antagonistSB242084andrikkunshitoonfoodintakeoftumor-bearingratsandblockadebytheghrelin
receptor(GHS-R)antagonist(D-Lys3)-GHRP-6(n¼8–10).(h)Fastedgastrointestinal(GI)motoractivityintumor-bearingratsonday5.GhrelinincreasedthefrequencyofphaseIII-like
contractions (m) in the duodenum (n¼8). *Po0.05; **Po0.01. AgRP: agouti-related peptide; CART: cocaine- and amphetamine-regulated transcript; MCH: melanin-concentrating
hormone; OXT: oxytocin; UCN, urocortin.
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Translational Psychiatryrikkunshito (1000mgkg
 1). Gastric vagotomy eliminated
the stimulatory effect of ghrelin (10ng, intravenous) on
the efferent activities of the gastric vagus nerve, but did
not inﬂuence the effect of rikkunshito (1000mgkg
 1,
intraduodenal) or a 100-fold higher dose of ghrelin
(1000ng, intravenous) (Supplementary Figure S3).
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Figure 2 Involvement of corticotropin-releasing factor (CRF) in cancer anorexia. (a) The serotonin (5-HT)-induced cytosolic Ca
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(h, i) Ghrelin (10
 12moll
 1) increased the [Ca
2þ]i in single neuropeptide Y (NPY) neurons isolated from the arcuate nucleus (ARC). The increase in AUC of the [Ca
2þ]i in
response to secondary ghrelin with rikkunshito (n¼22) was signiﬁcantly greater than the response to primary or secondary ghrelin without rikkunshito (n¼32). *Po0.05;
**Po0.01.
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Translational PsychiatryGhrelin is predominantly produced in gastric X/A-like cells.
Rikkunshito elevated the gene expression of gastric ghrelin
and hypothalamic NPY genes in rats (Supplementary Figure
S4a). Rikkunshito did not acutely stimulate ghrelin secretion
from minced stomach tissues (data not shown), but normal-
ized the fenﬂuramine-induced decrease in ghrelin secretion
mediated by the 5-HT2cR in the brain (Supplementary Figure
S4b), suggesting that this is the centrally predominant site
of action.
Ghrelin (10
 7moll
 1) elicited an increase in [Ca
2þ]i of
GHS-R-expressing COS cells. Rikkunshito had no effect on
the [Ca
2þ]i in these cells. However, the ghrelin-induced
[Ca
2þ]i increase was enhanced by a 2-min pretreatment with
rikkunshito in a concentration-dependent manner, and
100mgml
 1 of rikkunshito signiﬁcantly enhanced the duration
of the [Ca
2þ]i increase induced by ghrelin (Figure 3c and d).
Rikkunshito enhanced the binding activity of [
125I]ghrelin to
the GHS-R (Figure 3e). We screened the 43 compounds
(100mmoll
 1) contained in rikkunshito. Two of these com-
pounds, atractylodin and atractylodinol, showed a marked
increase in ghrelin/GHS-R binding activity. Atractylodin also
sustained the ghrelin-induced [Ca
2þ]i increase in GHS-R-
expressing cells (Figure 3f and g).
Ghrelin increases the [Ca
2þ]i in the NPY neurons of the
hypothalamic ARC,
18 and this effect is linked to stimulation of
feeding.
19 Ghrelin, at a submaximal concentration of
10
 12moll
 1, increased [Ca
2þ]i levels in acutely isolated
fura-2-loaded rat ARC neurons, which were subsequently
shown to be NPY neurons by immunocytochemistry. Pre-
treatment with rikkunshito enhanced the ghrelin-induced
increase in [Ca
2þ]i compared with ﬁrst ghrelin or second
ghrelin administration without rikkunshito (Figure 3h and i).
These data indicate that rikkunshito potentiates the action of
ghrelin to increase the [Ca
2þ]i in NPY neurons in the ARC.
Survival. Daily administration of (D-Lys3)-GHRP-6
(4mmolkg
 1, i.p.; Figure 4a) decreased median survival in
AH-130 tumor-bearing rats, demonstrating the importance of
ghrelin signaling in cancer anorexia–cachexia. In contrast,
median survival in AH-130 tumor-bearing rats was
signiﬁcantly increased by the daily administration of
rikkunshito (250 and 500mgkg
 1, per os; Figure 4b) and
atractylodin (1mgkg
 1, per os; Figure 4c), but not SB242084
(5mgkg
 1, per os) or ghrelin (3nmol, i.p.) (Supplementary
Figure S5). Rikkunshito also exhibited a positive effect
on survival in CT-26 colon carcinoma-bearing mice
(Supplementary Figure S6). Survival in tumor-bearing rats
was also increased by administration of cisplatin (CDDP;
1mgkg
 1, i.p.), and 6 of 27 rats survived until the end of the
experimental period. Administration of rikkunshito further
prolonged survival in CDDP-treated tumor-bearing rats
(Figure 4d).
The beneﬁcial effect of rikkunshito on survival was also
demonstrated in human patients. Pancreatic cancer patients
with ascites received gemcitabine or gemcitabine plus
rikkunshito. There was no signiﬁcant difference between the
two groups in baseline data with respect to stage and age.
Median survival of pancreatic cancer patients with ascites
who were treated with gemcitabine was signiﬁcantly pro-
longed by administration of rikkunshito (Figure 4e).
Discussion
Weight loss is a potent stimulus of food intake in healthy
humans and animals, and ghrelin secretion increases under
conditions of negative energy balance such as starvation.
Increased concentrations of acyl ghrelin have been found in
patients
20,21 and mice
22 with various cancer diagnoses and
staging. These ﬁndings imply that the persistence of anorexia
in cancer patients is due to a failure of the adaptive feeding
response by ghrelin, which is robust in normal animals and
subjects.
23–25 We found that plasma acyl ghrelin concentra-
tions in tumor-bearing rats were higher than that in free-fed
normal rats, but lower than that in pair-fed normal rats, and
had an inverse relationship with plasma leptin concentrations.
These results indicate that changes in ghrelin and leptin
secretion in pair-fed animals represent a compensatory
mechanism in a persistent catabolic state and that these
responses are attenuated in tumor-bearing rats. The hypo-
thermia in tumor-bearing rats may be due to a state of
negative energy balance or a decrease in the threshold for the
activation of thermogenesis, which is involved in starvation-
induced hypothermia.
26 Interleukin-1b
17 and leptin
27 de-
crease the expression of ghrelin mRNA in the stomach,
whereas interleukin-6 produced in various cells, including
adipocytes, regulates leptin production.
28 These ﬁndings
suggest that cytokines have an important role in energy
balance through the persistent activation of the leptin system
and the inhibition of the ghrelin-NPY/agouti-related peptide
orexigenic network in tumor-bearing rats. In addition to NPY
and agouti-related peptide, the level of POMC mRNA was
alsodecreasedinthehypothalamusofthetumor-bearingrats.
Synaptic input organization and mRNA expression of POMC
neuronhavebeenshowntobeincreasedinadrenalectomized
animals and restored by corticosterone replacement.
29 Thus,
activity of hypothalamic POMC neuron may be affected by
changes in circulating levels of corticosterone and a state of
negative energy balance.
Peripheral ghrelin administration stimulates food intake in
melanomacell-bearingmiceandcancerpatients
30intheshort
term as well as in lean, healthy men and women.
31 In this
study, we found similar therapeutic effects of ghrelin on
anorexia and GI dysmotility in cachectic animal models,
suggesting that high plasma concentrations of ghrelin may
overcome resistance to the appetite-stimulating effects of the
endogenous peptide in the short term. Rikkunshito, which
mimics these ghrelin effects, effectively improved food intake
andGImotoractivitiesinthisstudy.Rikkunshitoisatraditional
herbal medicine used to treat GI tract disorders such as
functional dyspepsia
32–36 and gastroesophageal reﬂux.
37
Oral administration of rikkunshito increases plasma acyl
ghrelin levels in humans, mice,
38 rats
14,15 and dogs (data
not shown). Rikkunshito stimulates ghrelin secretion
through 5-HT2b/2c receptor antagonism, and its active
ﬂavonoid ingredients such as hesperidin that antagonize
5-HT2b/2c receptor binding have been identiﬁed.
14 In addi-
tion, rikkunshito and 5-HT2cR antagonist suppress cisplatin-
induced anorexia by inhibiting reduction of GHS-R1a gene
expression in the hypothalamus.
39
The central 5-HT system has been implicated in the
processes of meal satiation and satiety. 5-HT reuptake
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attenuate food intake and weight gain in rodents and
humans,
40–42 with the involvement of potentiated MC signal-
ing and decreased ghrelin secretion. 5-HT also inhibits NPY/
agouti-related peptide neurons by activating the 5-HT1bR,
leading to decreased orexigenic signaling and an inhibitory
drive onto POMC cells. However, our previous study
suggested that the 5-HT2cR has a major role in the regulation
of physiological fasted and fed motor activities in addition to
feeding through changes in endogenous ghrelin.
15 In this
study, we found that the decreases in food intake and GI
motor activities in tumor-bearing rats were recovered after
administration of either a 5-HT2cR antagonist or ghrelin. The
5-HT concentration in the hypothalamus is increased in
humans and animals with cancer;
43,44 in addition, NPY and
dopamine concentrations decrease simultaneously, while 5-
HT concentration increases in the PVN at the onset of
anorexia in tumor-bearing rats.
45 These ﬁndings suggest that
5-HT2cR activation in tumor-bearing rats induces anorexia in
part via decreased ghrelin secretion.
We have previously shown that a central 5-HT2cR pathway
regulates ghrelin secretion without downstream activation of
melanocortin 3/4 receptors.
15 The 5-HT2cR is expressed in
many brain regions and its expression is restricted to the
central nervous system.
46 Dual-neurohistochemical labeling
has revealed that approximately one-half of PVN CRF-
containing neurons co-express 5-HT2cR mRNA.
47 In this
study, we found that 5-HT activated single CRF neurons
isolated from the PVN, and the activities of the CRF neurons
were blocked by simultaneous administration of rikkunshito.
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decreased plasma acyl ghrelin in fasted rats. These ﬁndings
suggest that CRF neurons are involved in 5-HT-regulated
ghrelin secretion. Hypothalamic 5-HT and CRF activities are
stimulated by proinﬂammatory cytokines in the circulation and
the hypothalamus.
13,48 Here we demonstrate that a CRF
receptor antagonist improved cancer anorexia–cachexia, and
that administration of the 5-HT2cR antagonist or rikkunshito
reduced hypothalamic CRF levels and anxiety-related beha-
viors in tumor-bearing rats. The improvement in anxiety by
rikkunshito may lead to a higher quality of life in cancer
patients. Some studies suggest that ghrelin induce anxiogen-
esis, whereas others suggest that the elevated ghrelin helps
animals cope with stress by producing anxiolytic-like re-
sponse.
49 Future studies are needed to sort out the effect of
ghrelin on anxiety-like behavior as in the case for NPY.
50
Importantly, our ﬁndings demonstrate that a hypothalamic 5-
HT-CRF receptor pathway that regulates ghrelin secretion
has a major role in cancer anorexia–cachexia.
The GHS-R is reportedly expressed in vagal afferent
neurons, and the gastric vagus nerve system is involved in
the effect of ghrelin on food intake and GI motor activities.
51,52
We demonstrated that ghrelin decreased the afferent activity
of the gastric vagus nerve. Gastric ghrelin signaling via vagal
afferents stimulated the efferent activities of both the gastric
and the celiac branches of the vagus nerve and suppressed
the activity of the sympathetic nerve. Peripheral administra-
tion of a higher dose of ghrelin increased the discharge rate of
the vagal efferent nerve, probably in part through the GHS-R
in the ARC of the hypothalamus. We also showed that
rikkunshito activated the efferent vagus nerve, which may be
mediated by both the vagal afferent nerve and the direct
central action (Figure 5). In addition, we found that ghrelin-
induced cellular signaling in GHS-R-expressing cells was
enhanced by pretreatment with rikkunshito and its active
components, such as atractylodin, which stimulate ghrelin/
GHS-R binding activity. Similar potentiating effects of
rikkunshito were observed in rat ARC NPY neurons. These
ﬁndings suggest that the physiological functions of endogen-
ous ghrelin are enhanced by the dual actions of rikkunshito,
which involve the stimulation of ghrelin secretion and the
activation of GHS-R activity, possibly due to allosteric
changes in the receptor. This potentiation of the ghrelin effect
by rikkunshito on NPY neurons could be orexigenic because
the activity of ghrelin-responsive NPY neurons is coupled to
feeding.
19,53
Our study indicated the adverse effect of (D-Lys3)-GHRP-6
on survival in tumor-bearing rats, suggesting that the
potentiation of ghrelin signaling is critical to the attenuation
of anorexia–cachexia and the prolongation of survival in
subjects with cancer. Rikkunshito and its active component,
atractylodin, prolonged survival in these animals, and this
effect was enhanced by the concomitant administration of
CDDP. Cancer patients receiving chemotherapy or radiation
therapy may experience nausea, vomiting, taste changes,
stomatitis and diarrhea, which could contribute to weight
loss and decreased survival. Therefore, cancer anorexia–
cachexia syndrome is a major obstacle in cancer chemother-
apy.
6 Rikkunshito was recently reported to suppress
decreases in plasma acyl ghrelin levels and CDDP-induced
anorexia.
14 Our use of rikkunshito in tumor-bearing rats was
effective not only against anorexia–cachexia, but also for
promoting survival, particularly in combination with chemo-
therapy. Daily administration of a 5-HT2c receptor antagonist
failed to prolong survival, suggesting that a sensitizing effect
on the GHS-R may be essential for ameliorating ghrelin
resistance in anorexia–cachexia in the long term. Pancreatic
cancer patients generally respond poorly to chemotherapy,
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Figure 5 Ghrelin signaling and cancer anorexia–cachexia. Hypothalamic
corticotropin-releasing factor (CRF) neurons are activated by cytokines through
serotonin (5-HT) and the 5-HT 2c receptor (5-HT2cR), which shows functional
divergence.
15 Our data demonstrate the existence of a novel 5-HT-CRF neuronal
pathway that inhibits ghrelin secretion and has a pathogenetic role in cancer
anorexia–cachexia syndrome. The traditional herbal medicine rikkunshito improves
anorexia, weight loss, gastrointestinal (GI) dysmotility, anxiety-related behavior and
survival.Rikkunshitoanditsactivecomponenthesperidinstimulateghrelinsecretion
from stomach by interrupting this 5-HT-CRF pathway via 5-HT2cR antagonism.
Another active component atractylodin potentiates the action of ghrelin by
presumably allosterically sensitizing the GHS-R on the vagal afferent terminals of
stomach or neuropeptide Y (NPY) neurons of the hypothalamic arcuate nucleus
(ARC). The 5-HT2cR antagonist improved anorexia–cachexia in the short term, but
failed to improve survival. Thus, both the release of ghrelin and the potentiation of
ghrelin/GHS-R signaling are important for mitigating ghrelin insufﬁciency and
resistance, which are characteristics of cancer anorexia–cachexia syndrome.
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found that the median survival of pancreatic cancer patients
treated with gemcitabine was prolonged by the addition of
rikkunshito, particularly for those with ascites. These results
suggest that rikkunshito may be useful in clinical practice for
cachectic cancer patients via its dual action on ghrelin
secretion and receptor sensitization.
Inconclusion,ourstudydemonstratesthatcanceranorexia–
cachexia is mediated by decreased ghrelin/GHS-R signaling
as a result of excessive hypothalamic interactions of 5-HT and
CRF through the 5-HT2cR. Decreased ghrelin signaling is an
important integrated mechanism linking anorexia, body weight
loss, GI dysmotility, anxiety-related behavior and decreased
survival. Potentiation of ghrelin signaling introduces a novel
approachforthetreatmentofcanceranorexia–cachexia,which
is characterized by ghrelin insufﬁciency and resistance.
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